HomeSite MapContact Us

News

Recent News

Jun 17, 2014 –  Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout
Jun 17, 2014 –  Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout
Jun 17, 2014 –  Selecta Biosciences to Accelerate Program for Novel Dual Action Vaccine for Malaria with support from the Bill & Melinda Gates Foundation
Dec 9, 2013 –  Selecta Biosciences Announces Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy
Dec 9, 2013 –  USPTO Allows First In a Series of Selecta Patents for Immune Tolerance
Aug 27, 2013 –  Selecta Biosciences Distinguished as World Economic Forum Technology Pioneer 2014
Nov 28, 2012 –  Selecta and Sanofi Sign Global Collaboration
Nov 28, 2012 –  Selecta (RUS) LLC becomes RUSNANO’s first foreign portfolio company in the pharmaceutical sector to open a research center in Russia
May 9, 2012 –  Selecta Receives 2012 Edison Awards Gold Medal
Nov 21, 2011 –  Selecta Biosciences Initiates Phase 1 Clinical Study of SEL 068
Oct 27, 2011 –  RUSNANO invests in Selecta Biosciences and BIND Biosciences
Oct 27, 2011 –  Selecta Announces 47 25 Million Financing
Sep 6, 2011 –  FierceBiotech Names Selecta Biosciences a 2011 Fierce 15 Biotech
Aug 31, 2011 –  Selecta Appoints Kishimoto
Aug 31, 2011 –  Selecta Biosciences Awarded Subcontract
Jun 9, 2011 –  Selecta Biosciences Appoints Peter Keller as Vice President of Business Development and Alliance Management
Jun 9, 2011 –  The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes
Aug 16, 2010 –  Selecta Biosciences Appoints Werner Cautreels, Ph.D., as Company’s First CEO
Aug 16, 2010 –  Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation
Apr 5, 2010 –  Selecta Closes $15 Million Series C Financing
Oct 29, 2009 –  Selecta Co-Founder Named 2009 Mass High Tech All Star
Feb 25, 2009 –  Selecta Biosciences closes $15.1M Series B Financing
Oct 8, 2008 –  Selecta Biosciences Forms Distinguished Scientific Advisory Board
Sep 4, 2008 –  Selecta Biosciences Appoints Lloyd Johnston, Ph.D., as Vice President, Pharmaceutical Research and Development

© 2014 Selecta Biosciences, Inc.  |  480 Arsenal St., Building One, Watertown, MA 02472  |  Phone: 617-923-1400  |   Fax: 617-924-3454  |  Email: info@selectabio.com
Privacy Policy  |  Web site designed and developed by RainCastle Communications, Inc.